Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome.
Notice bibliographique
Résumé
e24092 Background: The combination of dabrafenib and trametinib has been used to treat many malignancies featuring BRAF mutations. The most common adverse event observed in patients on dabrafenib/trametinib is pyrexia syndrome. Pyrexia syndrome is defined by the Canadian Working Group as fever > 38 o C and/or chills, rigors, night sweats, and flu-like symptoms in the absence of infection. They further defined severe/complicated pyrexia as pyrexia syndrome requiring hospitalization, or complicated by CTCAE grade 2 or higher dehydration, hypotension, renal dysfunction, confusion, or vomiting. Here, we report the incidence of pyrexia and severe/complicated pyrexia associated with dabrafenib/trametinib at the University of Rochester Wilmot Cancer Center, and discuss the potential prognostic significance of pyrexia syndrome. Methods: We collected retrospective data on patients treated with dabrafenib and trametinib between 2015 and 2022. For each patient, we recorded the number of episodes of pyrexia and severe/complicated pyrexia. Additional information was collected on the type of malignancy, duration of therapy, and whether treatment was terminated due to an adverse event or disease progression. For each episode of pyrexia, analysis was performed to rule out infection. All cases for which the presence of infection was ambiguous were reviewed by an infectious disease specialist. Results: We reviewed 109 patients treated at our institution with dabrafenib and trametinib. 88 patients had complete outcomes data and were included in the final analysis. Melanoma was the most common malignancy followed by lung cancer, thyroid cancer, and glioma. 39% of patients developed pyrexia syndrome and 16% developed severe/complicated pyrexia. The median time to development of pyrexia syndrome was 1 month. On average, patients included in our study were on dabrafenib/trametinib for 12 months. Patients who developed pyrexia were more likely than patients who did not develop pyrexia to discontinue therapy due to an adverse event (32% vs 22%), and patients who developed severe/complicated pyrexia were even more likely to discontinue treatment (43%). However, patients who developed pyrexia on average remained on therapy for a longer period than patients who did not develop pyrexia (17 vs 9 months). Furthermore, patients who developed severe/complicated pyrexia remained on therapy for even longer (26 months). Conclusions: Pyrexia syndrome is the most common adverse event in patients treated with dabrafenib and trametinib. While patients who develop pyrexia and severe/complicated pyrexia are more likely to require their medication to be discontinued, they also remain on treatment for longer periods, suggesting that pyrexia may be a positive prognostic marker of treatment efficacy. This speaks to the importance of developing strategies for the management of pyrexia syndrome.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,001 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».